Oppenheimer Reiterates Outperform and PT of $21 on MedAssets

Oppenheimer reiterated its Outperform rating on MedAssets MDAS. At the same time, Oppenheimer left its price target on the company's stock unchanged at $21. In today's trading, MedAssets added 0.04% to its value to trade around $13.20.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: ReiterationAnalyst RatingsHealth CareHealth Care TechnologymedassetsOppenheimer
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!